Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorNKONGOLO, Shirin
dc.contributor.authorNUSSBAUM, Lea
dc.contributor.authorLEMPP, Florian A
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorWODRICH, Harald
dc.contributor.authorURBAN, Stephan
dc.contributor.authorNI, Yi
dc.date.accessioned2023-11-13T13:35:05Z
dc.date.available2023-11-13T13:35:05Z
dc.date.issued2019-08-01
dc.identifier.issn1872-9096en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/184737
dc.description.abstractEnChronic infection with the human Hepatitis B virus (HBV) is a major global health problem. Hepatitis D virus (HDV) is a satellite of HBV that uses HBV envelope proteins for cell egress and entry. Using infection systems encoding the HBV/HDV receptor human sodium taurocholate co-transporting polypeptide (NTCP), we screened 1181 FDA-approved drugs applying markers for interference for HBV and HDV infection. As one primary hit we identified Acitretin, a retinoid, as an inhibitor of HBV replication and HDV release. Based on this, other retinoic acid receptor (RAR) agonists with different specificities were found to interfere with HBV replication, verifying that the retinoic acid receptor pathway regulates replication. Of the eight agonists investigated, RARα-specific agonist Am80 (tamibarotene) was most active. Am80 reduced secretion of HBeAg and HBsAg with ICs 12 days after removal of the drug. HBV genotypes B, D, and E were equally inhibited. By contrast, Am80 did not affect HBV replication in transfected cells or HepG2.2.15 cells, which carry an integrated HBV genome. In conclusion, our results indicate a persistent inhibition of HBV transcription by Am80, which might be used for drug repositioning.
dc.language.isoENen_US
dc.subject.enAcitretin
dc.subject.enAntiviral Agents
dc.subject.enBenzoates
dc.subject.enCells
dc.subject.enCultured
dc.subject.enDNA
dc.subject.enCircular
dc.subject.enDNA
dc.subject.enViral
dc.subject.enHepatitis B Surface Antigens
dc.subject.enHepatitis B e Antigens
dc.subject.enHepatitis B virus
dc.subject.enHepatitis Delta Virus
dc.subject.enHepatocytes
dc.subject.enHumans
dc.subject.enRNA
dc.subject.enViral
dc.subject.enReceptors
dc.subject.enRetinoic Acid
dc.subject.enTetrahydronaphthalenes
dc.subject.enTranscription
dc.subject.enGenetic
dc.title.enThe retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA.
dc.title.alternativeAntiviral Resen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.antiviral.2019.04.009en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed31018112en_US
bordeaux.journalAntiviral Researchen_US
bordeaux.page146-155en_US
bordeaux.volume168en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04282438
hal.version1
hal.date.transferred2023-11-13T13:35:08Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Antiviral%20Research&rft.date=2019-08-01&rft.volume=168&rft.spage=146-155&rft.epage=146-155&rft.eissn=1872-9096&rft.issn=1872-9096&rft.au=NKONGOLO,%20Shirin&NUSSBAUM,%20Lea&LEMPP,%20Florian%20A&WODRICH,%20Harald&URBAN,%20Stephan&rft.genre=article


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée